Clinical Trial

Dose-escalation Study to Evaluate the Safety and Tolerability of GS030 in Subjects With Retinitis Pigmentosa

Study acronym: PIONEER
Active, Not Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
The objective of this study is to evaluate the safety and tolerability of escalating doses of a gene therapy called GS030-DP (injected study treatment) administered via a single intravitreal injection and repeated light stimulation using a medical device called GS030-MD (stimulating glasses) in subjects with documented diagnosis of non-syndromic Retinitis Pigmentosa
Protocol Amendment History 11 amendments
This ClinicalTrials.gov record has been amended 11 times since 2017-10-25; most recent amendment 2026-02-27.
Status change: Recruiting → Active, Not Recruiting 2025-08-20
Status change: Not Yet Recruiting → Recruiting 2019-03-15
Trial Details
NCT Number NCT03326336
Lead Sponsor GenSight Biologics
Conditions Non-syndromic Retinitis Pigmentosa
Enrollment 10 participants
Start Date 2018-09-26
Primary Completion 2027-10-26 (estimated)
Study Completion 2027-10-26 (estimated)
Updated on ClinicalTrials.gov 2026-03-02